# CLOZAPINE-RELATED BRAIN NRN1 EXPRESSION PATTERNS ARE ASSOCIATED WITH **METHYLATION AND GENETIC VARIANTS IN SCHIZOPHRENIA**

Carmen Almodóvar-Payá<sup>1,2,3,#,a</sup>, Marcos Moreno<sup>4,#</sup>, Maria Guardiola-Ripoll<sup>1,5</sup>, Mariona Latorre-Guardia<sup>1,2</sup>, Benito Morentin<sup>6,7</sup>, Beatriz Garcia-Ruíz<sup>1,2,8</sup>, Edith Pomarol-Clotet<sup>1,2</sup>, Luis F. Callado <sup>2,7,9</sup>, Carme Gallego<sup>4,+</sup>, Mar Fatjó-Vilas<sup>1,2,3+,a</sup>.

- 1. FIDMAG Germanes Hospitalàries Research Foundation, Barcelona, Spain.
- 2. CIBERSAM (Biomedical Research Network in Mental Health; Instituto de Salud Carlos III), Spain.

3. Department of Evolutionary Biology, Ecology and Environmental Sciences, University of Barcelona (UB), Barcelona, Spain.

- 4. Department of Cell and Tissues, Molecular Biology Institute of Barcelona (IBMB-CSIC), Barcelona, Spain.
- 5. CIBERER (Biomedical Research Network in Rare Diseases; Instituto de Salud Carlos III), Spain.
- 6. Section of Forensic Pathology, Basque Institute of Legal Medicine, Bilbao, Spain
- 7. BioBizkaia Health Research Institute, Bizkaia, Spain.
- 8. Institut d'Investigació Sanitària Pere Virgili (IISPV)-CERCA, Tarragona, Spain
- 9. Department of Pharmacology, University of the Basque Country (UPV/EHU), Bizkaia, Spain.
- # Co-first authors: C Almodóvar-Payá and M Moreno
- + Co-senior authors: C Gallego and M Fatjó-Vilas

<sup>a</sup> Corresponding authors: C Almodóvar-Payá (calmodovar@fidmag.org) and M Fatjó-Vilas (mfatjovilas@fidmag.org)

## ABSTRACT

The Neuritin-1 gene (NRN1), involved in neurodevelopment and synaptic plasticity, is associated with schizophrenia (SZ) and related clinical, cognitive, and neuroimaging phenotypes. Additionally, it is one of the most differentially methylated genes in the prefrontal cortex (PFC) in SZ and is responsive to neurotherapeutic agents. We aimed to investigate NRN1's molecular mechanisms in SZ by analyzing its expression, methylation, and genotypic profiles in PFC and hippocampus (HIPP) post-mortem samples from 30 control (CTL) subjects and 20 individuals with SZ (10 treated with clozapine, SZ-Clz, and 10 without antipsychotic drugs at death, SZ-ApFree). We compared the NRN1 mRNA expression between groups, measured by qPCR, and methylation levels across three CpG islands, assessed through EpiTYPER. Sparse Partial Least Square Discriminant Analysis identified key CpG units contributing to group differences. We then explored the relationship between NRN1 methylation and expression, considering the influence of 11 polymorphisms genotyped by gPCR. We found that SZ-Clz had lower NRN1 mRNA levels in the PFC than SZ-ApFree and CTL. SZ-Clz presented distinct methylation patterns across multiple CpG units in both brain regions compared to CTL. In the PFC, the methylation of the CpG units differentiating SZ-Clz from CTL correlated to NRN1 expression, and the NRN1-rs12333117 and NRN1-rs2208870 polymorphisms influenced this effect. These findings reveal distinct correlations between NRN1 epigenetic expression in SZ-Clz and CTL, shaped by genotypic variability. They emphasize region-specific alterations in SZ and underscore the importance of integrative approaches for a better understanding of the role of candidate genes in SZ etiology.

## **KEY WORDS**

NRN1, schizophrenia, post-mortem brain tissue, methylation, expression, clozapine

## 1 1. BACKGROUND

2 Despite schizophrenia (SZ) research progress, central pathophysiological mechanisms, molecular diagnostics, 3 or precise biomarkers persist unclear. SZ is widely acknowledged to have a high ~80% heritability (1,2), with 4 a complex polygenic architecture involving numerous genetic variants (3). Large-scale genome-wide 5 association studies (GWAS) have identified around 270 loci, many related to synaptic plasticity genes (4). 6 However, these variants incompletely explain total heritability, with most not directly affecting protein structure 7 but notably enriched for variants affecting DNA methylation, gene expression, and gene splicing in the human 8 brain during different developmental stages (5). Together, these findings suggest that both genetic factors and 9 epigenetic mechanisms regulating gene expression contribute to the developmental origins of SZ.

Among studies on epigenetic mechanisms, DNA methylation has been extensively researched, particularly in promoter regions for transcriptional repression, but it also regulates gene expression in distal elements like enhancers, exonic regions, and gene bodies, either inhibiting or activating expression based on genomic context (6). In the brain, methylation plays a twofold role: during development, the balance between methylation of germline-specific genes suppresses pluripotency, and demethylation of neuron-specific genes is key to facilitate neuronal specialization; in the mature brain, methylation changes can be induced by neuronal activity, contributing to complex cognitive processes such as learning and memory (7,8).

Methylation and gene expression studies in SZ, often performed utilizing prefrontal cortex (PFC) or 17 18 hippocampus (HIPP) tissues, have shown distinct methylation patterns in genes critical for neuron 19 development, synaptogenesis, and synaptic plasticity (9), as well as differential expression of genes related to 20 immune response and inflammation, mitochondrial energy metabolism, myeloid leukocyte activation, 21 cytoskeletal proteins, ion transport regulation, neurite outgrowth, and synaptic plasticity (10). Both types of 22 studies have also suggested that these differences may be region and even cell-specific, with distinct genes 23 implicated accordingly (11). Moreover, considering the impact of methylation on gene expression, numerous 24 studies have correlated promoter hypomethylation of genes related to dopaminergic (DRD2, DRD3, COMT), 25 GABAergic (GAD1), serotonergic (HTR2A), oligodendrocyte (SOX10), and synaptic plasticity (RELN) 26 pathways in brain samples from patients with SZ with increased gene expression (12–15).

The above-mentioned studies collectively indicate that exploring methylation's influence on expression in genes involved in brain development and synaptic plasticity might be key to understanding the biological underpinnings of SZ. The Neuritin1 gene (*NRN1*) exemplifies this, as it supports neuronal progenitors and differentiated neurons during early development (16), promotes the growth and stabilization of axonal and dendritic arbors, and facilitates synapse maturation in later development (17), while it also participates in adult

brain synaptic plasticity, particularly in the PFC and the HIPP (18,19). Although NRN1 has received less 32 33 attention than traditional GWAS candidate genes, its chromosomal region is linked to an SZ subtype marked 34 by cognitive deficits (20) and genetic association studies have related NRN1 variants to the risk for SZ, 35 cognitive deficits, early onset, and changes in brain structure and function (21-24). Additionally, two studies 36 comparing patients with SZ to control subjects (CTL) have pinpointed NRN1, firstly, as one of the most 37 differentially methylated genes in the PFC in SZ, and secondly, as one of the differentially expressed genes significantly contributing to patient differentiation according to transcriptomic clustering (25,26). Also, various 38 39 cellular and animal models have shown that NRN1 expression changes directly impact brain function and that 40 antipsychotic treatments can induce such changes. In animal models, increased Nnr1 expression has been 41 linked to better cognitive performance (27), improved recovery after ischemia-reperfusion injury (28), and 42 protective effects in traumatic brain injury (29). Similarly, Nrn1 expression responds to neurotherapeutic agents 43 like electroconvulsive therapy and fluoxetine through epigenetic pathways involving histone deacetylation (30,31). These findings suggest that modulating the NRN1 expression could improve SZ symptoms and 44 45 highlight its potential as a therapeutic target.

46 Among individuals with SZ undergoing antipsychotic therapy, special attention is given to those with a 47 treatment-resistant profile, which affects about one-third of cases and significantly lowers their quality of life 48 (32). Clozapine, the first atypical antipsychotic, has shown effectiveness in this group (33). It binds to various 49 receptors (34), including dopamine, serotonin, histamine, muscarinic, and adrenergic receptors. Although the 50 exact molecular pathways critical to its effectiveness are unclear, animal studies suggest that clozapine 51 improves behavioral outcomes by modulating genes related to cholesterol metabolism, GABAergic function, 52 cell cycle control, neurotrophins, and synaptic plasticity through reducing methylation or producing histone 53 modifications (35). Meanwhile, human studies are constrained by limited access to post-mortem brain samples 54 and the infrequent use of this treatment among patients. One study using publicly available SZ transcriptomic 55 data found that three genes (GCLM, ZNF652, GYPC) and four pathways involved in protein trafficking, 56 neuronal migration, brain development, and synaptic function were consistently differentially expressed in 57 clozapine-treated patients compared to those on other medications (36).

58 Overall, current data highlights the role of genetic variability and gene expression regulatory mechanisms, 59 such as methylation, in developmental abnormalities and the brain's response to stimuli, contributing to SZ 60 pathophysiology. Antipsychotics seem to modulate these epigenetic marks, suggesting new therapeutic 61 targets. Therefore, this study aimed to investigate expression, methylation, and genotype variability of *NRN1*,

a synaptic plasticity gene linked to SZ and sensitive to neurotherapeutic agents, in post-mortem PFC and HIPP
 samples from CTL and patients, considering antipsychotic treatment as a key factor.

#### 64 2. METHODS

#### 65 **2.1. Post-mortem human brain samples description**

66 Human post-mortem brain samples were collected at the Basque Institute of Legal Medicine (Bilbao, Spain), following research and ethics committee guidelines (Law 14/2007 and RD 1716/2011). It comprised 50 67 subjects, 20 with an ante-mortem diagnosis of SZ and 30 CTL. The diagnosis was performed by a qualified 68 69 psychiatrist according to DSM-IV or ICD-10 criteria, as recorded in subjects' medical records. Control subjects 70 had no evidence of any psychiatric disorder in their medical records. Exclusion criteria for both groups included neurological conditions and substance abuse. Post-mortem brain samples from the dorsolateral PFC 71 72 (Brodmann's area 9) and the HIPP, excluding white matter, were dissected at the time of autopsy and 73 immediately stored at -80°C until posterior analyses. Blood samples of those subjects were used for 74 toxicological screening for antidepressants, antipsychotics, psychotropic drugs, and ethanol performed at the 75 National Institute of Toxicology (Madrid, Spain). For CTL, selection ensured the absence of antidepressants 76 or antipsychotic drugs at the time of death. Finally, both groups were selected to be matched by sex, age, and 77 post-mortem interval (PMI), referring to the time elapsed between the death and the autopsy. Subjects with 78 SZ were subsequently divided according to the presence of clozapine (SZ-Clz) or the absence of antipsychotic 79 medication (SZ-ApFree) in the blood at the time of death. The summary of demographics and sample quality 80 is shown in Table 1 (see Table S1 for individual details).

medRxiv preprint doi: https://doi.org/10.1101/2024.10.29.24315982; this version posted November 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

#### perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

**Table 1.** Sample characteristics of control subjects (CTL) and individuals diagnosed with schizophrenia (SZ), categorized based on the presence of clozapine (SZ-Clz) or absence of antipsychotic medication (SZ-ApFree) in the blood at the time of death. Demographic information includes sex with female / male (F/M) count and frequency (%) for female category, age (in years), and cause of death. Assessment of post-mortem sample quality encompasses pH and post-mortem interval (PMI, in hours). All the quantitative variables are expressed as mean (standard deviation), while all the qualitative variables are presented as count (percentage). N=natural, O=others (including accidents and homicides), S=suicide.

				p-value
10 (33.3%) / 20	3 (30.0%) / 7	4 (40.0%) / 6	0.238	0.888
44.03 (12.10)	46.20 (10.14)	48 (14.90)	0.804	0.658
11 (37%) / 19 (63%) / 0	5 (50%) / 3 (30%) / 2	4 (40%) / 1 (10%) / 5	2.397	0.302
14.13 (6.65)	16.00 (4.81)	19.20 (4.13)	5.589	0.061
6.37 (0.35)	6.44 (0.28)	6.38 (0.29)	0.920	0.631
	44.03 (12.10) 11 (37%) / 19 (63%) / 0 14.13 (6.65)	44.03 (12.10) 46.20 (10.14) 11 (37%) / 19 (63%) / 0 5 (50%) / 3 (30%) / 2 14.13 (6.65) 16.00 (4.81)	44.03 (12.10)       46.20 (10.14)       48 (14.90)         11 (37%) / 19 (63%) / 0       5 (50%) / 3 (30%) / 2       4 (40%) / 1 (10%) / 5         14.13 (6.65)       16.00 (4.81)       19.20 (4.13)	44.03 (12.10)       46.20 (10.14)       48 (14.90)       0.804         11 (37%) / 19 (63%) / 0       5 (50%) / 3 (30%) / 2       4 (40%) / 1 (10%) / 5       2.397         14.13 (6.65)       16.00 (4.81)       19.20 (4.13)       5.589

<sup>a</sup> This analysis compares SZ-Free with SZ-Clz, as CTL did not die by suicide according to the inclusion criteria.

<sup>b</sup> Data for pH was available for 27 CTL, 9 SZ-Clz and 6 SZ-ApFree.

### 81 2.2. Expression analyses

Total RNA was extracted using the NucleoSpin RNA Plus Kit (Cultek). RNA integrity and purity were analyzed 82 83 by agarose gel electrophoresis and spectrophotometry using a NanoDrop. Reverse transcription reaction was 84 performed with a maximum of 1µg of RNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche) with random hexamer oligonucleotides. For quantitative PCR (qPCR) quantification, 1µL of the reverse transcription 85 86 reaction was added to the qPCR reaction using JumpStart Taq ReadyMix for quantitative PCR (Sigma). qPCR 87 reaction was preceded with an initial denaturation step at 94°C for 5 minutes followed by 45 cycles of: 88 denaturation at 94°C for 15s, annealing at 51°C for 20s, and extension at 72°C for 30s. The fluorescent signal 89 resulting from the degradation of the TagMan probe (6xFAM/Black Hole Quencher1) was read at the end of 90 the amplification phase. The primer sequences and probes are described in Table S2.

#### 91 2.3. DNA extraction

Genomic DNA was extracted from post-mortem brain samples using the Quick-DNA Miniprep Plus Kit (Zymo
Research) and used for methylation and genotyping analyses.

#### 94 2.4. Methylation

95 Methylation analyses targeted the CpGs along the three CpG islands (CGI) spanning the *NRN1* gene (CGI1 96 chr6:5998917-5999730, CGI2 chr6:6002288-6004772 and CGI3 chr6:6006457-6006810, reference genome 97 UCSC-GRC38/hg38). Samples were analyzed using the EpiTYPER method (Agena Bioscience) at the Centro 98 Nacional de Genotipado (CEGEN, http://usc.es/cegen/). This method examines CpG sites within amplicons 99 ranging from 200 to 600 base pairs, being especially well-suited for extensive endeavors aimed at investigating 99 specific regions. In our case, six amplicons were designed using Agena's EpiDesigner software to amplify 91 these regions of interest (**Table S3**).

The methylation values can range between 0 and 1, being 0 the value corresponding to a 0% methylation state and 1 the value associated with a 100% methylated state. If CpG sites are too close together, their methylation levels cannot be determined independently, so the methylation status of a fragment containing multiple sites is measured, reflecting the average methylation of all CpG sites within that fragment. Accordingly, we will refer to CpG units, which can comprise one or more CpG sites. Each CpG unit was denoted numerically based on its 5' to 3' genomic position on the forward strand sequence.


The methylation quality control protocol implemented by CEGEN involved excluding units deviating by over 10% from the established commercial controls (HMc, 100% methylated, and LMc, 0% methylated), as well as excluding the samples with standard deviation variances between replicas exceeding 10%. Additionally, we eliminated units and subjects with more than 35% missing values and replaced outlier methylation values with the maximum for z-scores  $\geq$  3 and the minimum for z-scores  $\leq$  -3. In all, we have analyzed 63 CpG units for the PFC and 57 CpG units for the HIPP along three CGIs within the *NRN1* region (see the details in **Figure 1** and **Table S4**).

#### 115 **2.5. Genotyping**

We genotyped eleven SNPs at the NRN1 gene (6p25.1) at the National Genotyping Center (CEGEN, 116 http://usc.es/cegen/) that were chosen to cover the genomic sequence and approximately 10 kb upstream and 117 118 downstream. The optimal set of SNPs, which contained the maximum information about surrounding variants, was selected using the SYSNPs tool (http://www.sysnps.org/) with a minor allele frequency (MAF) > 5%, 119 120 utilizing the pairwise tagging option ( $r^2 \ge 0.8$ ). Additionally, we included SNPs previously associated with SZ in 121 the study by Chandler et al. (2010). All these SNPs have also been genotyped in other studies conducted by 122 our group (21,21,23,37). The genotyping call rate was 100%, with minor allele frequencies closely matching those of the EUR population in the 1000 Genomes Project (Table 2). Genotype frequencies for both groups 123 were in Hardy-Weinberg equilibrium (PLINK v.1.09, (38)). 124

medRxiv preprint doi: https://doi.org/10.1101/2024.10.29.24315982; this version posted November 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



#### CGI1 (chr6:5998917-5999730) ATCTTCCTCTCGATTTCCGGGAGCAT

GGAGTGAGTGTGGGGTGGGCGCGCG GGGGGAGCTGGCCCCACGCTCAGAA GGAAAGCCAGGTCGCTAAAGCTGCC GAGAGAGACACCAGGAGCACCGGG AACGCCGGGAGCAGGGACCCCGCC GCCCCGTTGCCGCTGCCGCAGAGTT CGAATAAGCTGCCTTGGATGTTGAG GTTTTTGGATTCTTTTCTCAGTTTATC CCACATATCTTTCGCCCCTTCCTGGC AATCCGTAAGGGCTGTGACCGTGCA GCTGTGGAAATCCTCCCAGTATCTGG TGAGGAACAGAACAAAACAGAACAA GCAGGTTCACTTGGGACGCCGGGAA CACCCCGGGCTTGCGCCCTGCGCCT CCCCGCTGGCGGCCCCGCCAACTTCC CGGGGTGTCCCCTCCCTACCTTCTCT TCACCGCCCTGGCGCCTGGCCTGCG CGAGGTCGGGACTCGCGGGACCTCC GCCTACCCCAGAAGCGGCTGTCTAA AGCGGGGGTGGGGGGGGCGCCCCCT CCTGTCTGGTTTTCCCTTCCAGTTGCC GGGAGAGGACTAGGCAGCCGGGAG CCGGGCCGTGCACCCGCTGTGGCGC GCTGGCACCTCGGCCTCCGCAAACA GATTGCTCGCCCTCCTCGGGGAAAG CTAGGAAAACAGTGCTAAGCCTCGC AAGCTGCCGCCCATTAATGCCTCTTA GCTTGCAAGATGGGTTACTAGCTCT GAGCACGGCCCTCCCCTCGGGGCTT CTTACATTCTCCTCCCCCTCGCCCCTT CTGTCTCCCTCCTTCTCCACGCCGCG GTACTCTCGCCTTCG

CGI2 (chr6:6002288-6004772) ACGTGCACACGGTCTTGATGTTCGTCTTGTCGTCCAGGCCCTGCGGGTAGTTGGCCATGCTGTC GCCCAGCTTGAGCAAACAGTCCGAAAAGCCCTTGAAGACCGCATCGCACTTGCCCGCTGCTCTC CCCTGCCGCCCACTGCCCTTTCCTGCGAGACCCTGGCTCCGCGCGCCTCATCGCATCGGGCGG GAATGCCCGACCTGCAGCTAACGCTGCGTCTAGTGCAAATTGTCGGTGTGTGAGCAGGTGTGG GTGGGTGGGAGGTAGGTGAGTCCATTCCTTCCTCCAGCTCCCGCATCTCGCTCCGTATC CTCCTTCGTCTCCCAACACTTCCCCAGCAAGCCCTGTCACAGCTCTCGCAATGCGATCTTCCATT ACAGGGCGTGGGGTCACGCAGCTGAACCCAACGCCACATCACGAGAATAAGCCTCAGGCTTG ACGTCCTGAGACCTGGCGCGGATGATGAGGGGTGGTCTGGAGAGGAGAGGCCAGAGGCCGGGC GGGGTCACGGATGAGTCTGCCTGGGTCACCTCCGCAAAGGCCAAATCCACGAACCTCGGGCCT CCTGCTGCTGAAAGTGAGCTCGCCGCGGGCCCCGGGGCTCCTGGCCCCAGCTCAGGACTCCCTGC AGAGAGCAGGCAGGGATAAAAGCTGAGCGGCGGGAGGAGGAGGAGGAGGAGGAAACACAG GCCGCACGAAGGTCCAAGCCCCCAAGCCCCCGGCCTCTGGACGGCCAAACCCCCGAG CCTGAGGCCGACGAACCGGCTGGAAGCTGAGTGCCTAGCGGCCCAAAGCAGCCCGGGCGCC GGGAGGGCCCAGAGAAGCACAGCGTTAGGGCGGGAAGAAAGGGTGAATCTCAGAATCGA AATCCGCACTGGCGCCCACGACCCTGGGCGCCGGCCTGGTCCTCGGCAGCTTTCTGGCGGCTG CGCCTGTCCGCGAGCGCCGGGCCAGACGCCGAAGAGGAAGGTGACCGAACCCGTAGCAGCTT CCGAGAGCGTACCCGTTTGCAAATTGCTGCAGGAAGAGCGAGGCGGGCCTTGCGCTTTTAAT CCGGAACGGGAAGCACTGGGGGAAGGGACCGAGGTTAACTTCGACCTCCGCTGGGGCAGATAC GTAAACCTTCTCAAACCTCCGAGTTCACCTTACAGCGAACATTAAATACCCTTGCGACTACAATA CTAACAAATCGAACACTGACGTAAAATCTTAAGAATAAACGAATCTTTGTTCTGATAGAGCTCG TTCAAAATGGAAATACACTCCACACATCTTCCTCTATAACGCATGTCACAAATACAGCTTTGCAG AGAAGAAACGAAATAAAATAAAGTCCAATCTCCCCGTCCACGTCTCCCCCACCCCTTGCCTAC ACCCCCAAAACTCAGTGGCGAAAGAAGCCCCTAAAATGCATTGACATTTTTAAGGGGAATTG GGGCTCGCCGGGGGGCGGGGGGGCGCTCTTGTCACGTTATCTTCCCAGGCGCTGCTGGAGAAGACC CTGCACACCGCGCATGTGTGAGTGTGTGTGTGTGTAAAATAAGTCGTGAACATTTCTGTCTTTTA AAACTGTGACTCCTTGGACTCTAGCCTTCTCTGGGAGGCCGGGAGGCTGCGCGCGGGACGGAT TTTGCAGGCGCACGCGTCCCAGCAGGTCGCAGCCCGTGGGTCCCTCGCTGTCCTGAACCC CGCTTAGGCGAGACTCTAGCG

#### CGI3 (chr6:6006457-6006810)

CGTGTCCAGAAAATGTCCGGCCGCA CACATTTCCTGGCGAACATTTGGAAT CTATAGCTTTAGGAAAAACCGATCTG GGACGCGCTAGTCCCCAGGAACTGA TGCCCCCACCCTCGGGGGGATTGCCG GCTTCTCCGCACCCTGGGGCCGGCCG CGGACCCGCTAGTCCCCCTCCGCGCC TCGGGCCGGGGCAGGCTGCCTCCCG CCTCCAGCCTCCAGCCGGGCTGAGC GGCCACTTACCTATTTGCACCGCGAG GATCAGTGAAATATATCTGCCGTTCA ACTTAAGTCCCATCCTACGTTTAGTC AAACCATTTGCGACCGCAGACCTTTA AATAGTTAGTTTAGAGAACGCG

125 Figure 1. Schematic representation of the NRN1 gene (NCBI36/hg18) with exonic (in black) and CpG island (CGI, in blue) 126 regions, as well as single nucleotide polymorphisms (SNPs) included in the study according to the human genome browser 127

(http://genome.ucsc.edu). Positions of the analyzed CpG sites in the DNA sequence are indicated below (in bold blue).

medRxiv preprint doi: https://doi.org/10.1101/2024.10.29.24315982; this version posted November 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

**Table 2.** Information regarding *NRN1* SNPs included in this study. The table contains the dbSNP number, chromosome location (Chr Pos), alleles, and minor allele frequency (MAF) for each SNP based on the UCSC Genome Browser on Human (GRCh38/hg38). Additionally, MAF and genotypic count and frequency (%) are listed separately for control subjects (CTL) and subjects with schizophrenia (SZ), categorized based on the presence of clozapine (SZ-Clz) or absence of antipsychotic medication (SZ-ApFree) in the blood at the time of death. Due to low frequency in some genotypes, frequencies shown and subsequent analyses were conducted with all SNPs dichotomized (homozygous and heterozygous for the minor allele versus homozygous for the major allele).

dbSNP	Chr Pos	Allele	MAF <sub>1000G</sub>	MAF <sub>sample</sub>	CTL freq	SZ-ApFree (n=10)	SZ-Clz (n=10)
rs2208870	6:5992257	G/A	0.34	0.33	16 (53.3%) / 14	4 (40.0%) / 6	6 (60.0%) / 4
rs12333117	6:5994759	T/C	0.40	0.41	16 (53.3%) / 14	8 (80.0%) / 2	8 (80.0%) / 2
rs582186	6:6001148	A/G	0.38	0.43	20 (66.7%) / 10	6 (60.0%) / 4	6 (60.0%) / 4
rs645649	6:6004726	C/G	0.36	0.34	18 (60.0%) / 12	5 (50.0%) / 5	5 (50.0%) / 5
rs582262	6:6007758	C/G	0.30	0.32	18 (60.0%) / 12	6 (60.0%) / 4	4 (40.0%) / 6
rs3763180	6:6009615	T/G	0.46	0.48	22 (73.3%) / 8	7 (70.0%) / 3	7 (70.0%) / 3
rs10484320	6:6010204	T/C	0.22	0.20	10 (33.3%) / 20	2 (20.0%) / 8	2 (20.0%) / 8
rs4960155	6:6010306	C/T	0.49	0.52	22 (73.3%) / 8	8 (80.0%) / 2	8 (80.0%) / 2
rs9379002	6:6012158	G/T	0.29	0.28	14 (46.7%) / 16	7 (70.0%) / 3	5 (50.0%) / 5
rs9405890	6:6012488	C/T	0.31	0.26	12 (40.0%) / 18	3 (30.0%) / 7	4 (40.0%) / 6
rs1475157	6:6016936	G/A	0.17	0.19	10 (33.3%) / 20	5 (50.0%) / 5	3 (30.0%) / 7

#### 128 2.4. Statistical analysis

#### 129 2.4.1. Sample characteristics

For mean comparisons between cases and controls concerning sociodemographic and clinical characteristics
as well as biological quality of the sample, Wilcoxon Rank Sum Test (for quantitative variables) and chi-square
tests (for qualitative variables) were used.

#### 133 2.4.2. Expression analyses

Gene expression levels were determined with Delta Ct method (39), relativizing each gene expression to GAPDH levels. For the analysis, confounding variables (sex, age, death cause, PMI, and pH) were regressed from gene expression. Subsequently, a multifactorial ANOVA analysis was conducted followed by Tukey's

honest significance test, used for multiple comparisons of means between groups (CTL, SZ-ApFree and SZ-Clz).

#### 139 2.4.3. Methylation analyses

For methylation analyses, we assembled a subset consisting of 10 individuals each from the CTL, SZ-Clz, and SZ-ApFree groups, ensuring no significant differences with the initial sample in either demographic factors or post-mortem sample quality, as well as in *NRN1* expression across both regions (**Table S4** and **Figure S1**). Prior to analyzing methylation data, the confounding variables (sex, age, illness duration, and clozapine dosage) were regressed from each predictor methylation variable (CpG units).

145 To overcome the high intercorrelations among CpG units and the resulting multicollinearity (Table S5), we employed sparse Partial Least Squares-Discriminant Analysis (sPLS-DA), a method that simultaneously 146 147 performs dimensionality reduction, feature selection, and classification to examine methylation differences 148 between groups. Similar techniques, such as Principal Component Analysis (PCA), have been used in 149 methylation studies to reduce high-dimensional genomic or locus-specific data into principal components that capture overall variance among CpG units in an unsupervised manner (40,41). In contrast, sPLS-DA is a 150 151 supervised method that identifies latent components (LCs) by maximizing the covariance between the most relevant CpG units and group labels, enabling the discovery of methylation patterns associated with specific 152 groups and enhancing the clinical significance of the findings. 153

154 All the analyses were based on the mixOmics protocol as implemented in the R package (42). To address the 155 challenge posed by the small sample size in our study, we applied Leave-One-Out Cross-Validation (LOOCV) 156 at multiple stages of the modelling process to calculate classification error. LOOCV is particularly well-suited 157 to small datasets as it maximizes each data point's use by treating each individual sample as a test set once, while training the model on the remaining data. First, LOOCV was used to determine the optimal number of 158 159 LCs by evaluating the classification error across different component configurations. To further optimize the 160 model, we applied the LASSO penalty in combination with LOOCV to select the most relevant CpG units. After 161 determining the optimal number of LCs and CpG units, we used LOOCV to evaluate the performance of the 162 final sPLS-DA model. We interpreted each CpG unit within an LC in two main ways: first, through its coefficient 163 or loading value, which indicates its importance in distinguishing between groups, and second, by assessing 164 the contribution of the CpG, which identifies the group that shows higher methylation values. Additionally, to 165 validate the reproducibility of the CpG signature captured by the LCs, we performed a feature stability analysis, 166 which assessed how frequently each CpG site was selected across multiple iterations of the model.

We selected the most informative LC using two criteria: i) first, following the sPLS-DA methodology, where the first component captures the maximum covariance between features and the outcome, which we further validated by comparing LC scores between groups using the Mann-Whitney U test; and ii) second, based on the stability of CpG units within each LC, as subsequent analyses focused on examining methylation patterns defined by these CpG units.

To further characterize the CpG signature captured by the LCs and find methylation patterns, following other studies with similar approaches (43,44), we computed two means: one grouping CpG units showing greater methylation in the SZ group (referred as "positive mean"); and another grouping CpG units with lower methylation in the SZ group (referred as "negative mean"). To validate the robustness of these patterns and ensure that the observed differences were not merely the result of a data-driven process, we also utilized the Mann-Whitney U test to statistically compare these means between the two groups.

#### 178 2.4.4. Expression-methylation correlates

We conducted four linear regression analyses using the expression residuals of the HIPP or the PFC as described in section *2.4.2 Expression Analyses*. For each brain region, we tested two models: one with overall methylation variation (LC1) as the predictor and another with positive and negative mean methylation values as predictors.

#### 183 2.4.5. Genotypic analyses

We conducted four stepwise regression analyses using the expression residuals of the HIPP or the PFC as described in section *2.4.2 Expression Analyses*. For each brain region, we tested two models: one with overall methylation variation (LC1) with 11 *NRN1* genetic variants (SNPs) as the predictors and another with positive and negative mean methylation values with 11 *NRN1* genetic variants (SNPs) as predictors.

188 3. RESULTS

#### 189 **3.1. Sample description.**

There were no differences in sociodemographic nor in the quality of the biological sample between groups, as
they were matched for sex, age and PMI as shown in **Table 1**.

## 192 **3.2.** *NRN1* mRNA expression differences between groups.

193 We found group differences in the PFC (F=10.160 and p=0.002) but not in the HIPP (F=2.576 and p=0.088).

194 Tukey's post-hoc analysis showed that SZ-Clz had significantly reduced NRN1 mRNA expression levels in the

#### 195 PFC compared to CTL ( $\Delta$ -means=-7.10 and p-adj=0.007) and SZ-ApFree ( $\Delta$ -means=-8.85 and p-adj=0.005)

## 196 (**Figure 2**).

197





Figure 2. Boxplots representing NRN1 expression levels ± 2 standard errors (SE) depicted according to the group, control subjects (CTL), schizophrenia patients (SZ) categorized based on the presence of clozapine (SZ-Clz) or absence of antipsychotic medication (SZ-ApFree) in the blood at the time of death, for both brain regions: A) Prefrontal cortex (n=27, 9, and 9 respectively), and B) hippocampus (n=26, 9, and 10 respectively). The NRN1 expression was relativized to GAPDH, and the values expressed are the residuals (adjusted by sex, age, post-mortem interval (PMI), death cause (DC) and pH). Adjusted p-values from Tukey's test are represented as \* p<0.05, \*\* p<0.01, \*\*\* p<0.001.</p>

To validate the findings concerning *NRN1* expression we also analyzed the expression of two other synapserelated genes well described to be sensitive to clozapine treatment, *UMHK1* and *BDNF* (45). Like *NRN1*, significant group differences emerged within the PFC for both *UMHK1* (F=5.73, p=0.006) and *BDNF* (F=8.993, p<0.001), while not in the HIPP. Tukey's post-hoc analysis revealed that clozapine treatment was markedly associated with a decrease of *UMHK1* mRNA expression levels in the PFC compared to both CTL ( $\Delta$ -means=-2.589, p-adj=0.032) and SZ-ApFree ( $\Delta$ -means=-3.968, p-adj=0.005), while *BDNF* expression levels were notably higher compared to CTL ( $\Delta$ -means=1.307, p-adj < 0.001) (**Figure S2**).

## 211 3.3. NRN1 methylation differences between groups

Initially, our analysis encompassed all three groups, but we observed a limited ability to identify a specific linear combination of CpG units from either the PFC or the HIPP that could effectively differentiate between the three groups (balanced error for the model incorporating CpG units from the PFC=0.74 and from the HIPP=0.66). Furthermore, upon projecting the samples into the two LC spaces determined by the respective models, we observed a significant overlap between CTL and SZ-ApFree, but a clear distinction of SZ-Clz in both regions (Figure S3 and Figure S4).

218 Subsequently, we generated two separate models for each region, focusing on the CTL and SZ-Clz groups. In the PFC, three LCs explained 12%, 17%, and 10% of the methylation variance, respectively, effectively 219 220 distinguishing the groups (balanced error=0.28) (Figure 3A). Similarly, in the HIPP, two LCs explained 34% 221 and 22% of the variance, achieving the same level of separation (balanced error=0.28) (Figure 3C). Due to 222 the sPLS-DA methodology, LC1 was the most influential in differentiating the groups in both regions. This was further confirmed by significant differences observed in PFC-LC1 (W=76, p<0.001) and HIPP-LC1 (W=71, 223 224 p=0.005), while the other LCs did not reach statistical significance, neither in the PFC (LC2: W=62, p=0.06; LC3: W=51, p=0.38; Figure 3B) nor in the HIPP (LC2: W=61, p=0.08; Figure 3D). Additionally, PFC-LC1 and 225 226 HIPP-LC1 exhibited greater feature stability, with at least 88% of CpG units showing high stability (>85%), 227 compared to less than 50% in the other LCs (Table S6). Accordingly, subsequent analyses of methylation 228 patterns among the CpG units focused on LC1 in both regions.




229 Figure 3. A and C) Scatter plot illustrating the distribution of samples projected into the space defined by the first two 230 components derived from sparse Partial Least Square Discriminant Analysis (sPLS-DA) using NRN1 methylation values 231 from the hippocampus (HIPP). Each sample class is enclosed within 95% confidence ellipses. B and D) Boxplots 232 representing methylation scores for the first and second latent components (LC) ±2 standard errors (SE) depicted 233 according to the group. Control subjects (CTL) are depicted in purple while schizophrenia patients treated with clozapine 234 (SZ-Clz) are shown in blue. \* p<0.05, \*\* p<0.01, \*\*\* p<0.001.

235 In both brain regions, LC1 included 10 CpG units with varying importance in distinguishing between classes. 236 CpG units with positive weights, represented by red bars, exhibited higher methylation levels in SZ-Clz subjects 237 compared to CTL, while those with negative weights, shown in green, exhibited lower methylation levels in SZ-238 Clz subjects (Figure 4A and C). In both regions, the mean of the CpG units in LC1 with reduced methylation in SZ-Clz subjects compared to CTL significantly differed between groups ("PFC negative average": CpG3.8, 239 240 CpG2.5, CpG1.20, CpG2.6, CpG1.3, and CpG2.28, W=69, p=0.01; "HIPP negative average": CpG2.1, CpG2.2, CpG2.3, CpG2.5, and CpG3.3, W=70, p=0.008), suggesting that the observed differences are not 241 merely data-driven artifacts. In contrast, the mean of the CpG units in LC1 with higher methylation in SZ-Clz 242 243 subjects compared to CTL did not show significant differences in either region ("PFC positive average": CpG3.12, CpG1.2, CpG1.1, and CpG1.16, W=18, p=0.05, Figure 4B; "HIPP positive average": CpG1.19, 244 245 CpG3.1, CpG3.4, CpG2.21, and CpG1.20, W=31, p=0.44, Figure 4D).

medRxiv preprint doi: https://doi.org/10.1101/2024.10.29.24315982; this version posted November 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



246 Figure 4. A and C) Bar plots illustrating the loading weights for each CpG unit in component 1. Red bars indicate higher 247 methylation in patients with schizophrenia (SZ) treated with clozapine (SZ-Clz), while green bars represent lower 248 methylation in SZ-Clz compared to control subjects (CTL). B and D) Boxplots representing the mean methylation values, 249 computed based on whether the CpGs exhibited higher (positive mean) or lower (negative mean) methylation levels in SZ-250 Clz compared to CTL, ±2 standard errors (SE) depicted according to the group. SZ-Clz are shown in blue and CTL in 251 purple. \* p<0.05, \*\* p<0.01, \*\*\* p<0.001.

## 252 3.3. NRN1 expression methylation correlates

253 We observed a significant correlation between LC1 scores derived from the PFC sPLS-DA model and NRN1 gene expression in the corresponding brain region across the sample including both SZ-Clz and CTL groups 254 255 (standardized  $\beta$ =0.753, p<0.001, adj-R<sup>2</sup>=0.536). When we further analyzed the CpG units based on their methylation status in the SZ-Clz group, the correlation remained significant for the "negative mean" values 256 (standardized β=0.715, p=0.002, adj-R<sup>2</sup>=0.477), while the "positive mean" values were not associated with 257 258 NRN1 expression. These results indicate that lower LC1 scores or "negative mean" values are linked to a 259 reduced NRN1 expression (Figure 5 and Figure S5). Conversely, we did not find any correlation between 260 NRN1 expression and methylation in the HIPP.




Figure 5. Scatter plot illustrating the correlation between latent component 1 (LC1) scores derived from the sparse Partial Least Square Discriminant Analysis (sPLS-DA) of the prefrontal cortex (PFC) and *NRN1* gene expression levels in the same region. *NRN1* gene expression levels are shown with ±2 standard errors (SE). The expression of *NRN1* was normalized to GAPDH, and the values are presented as residuals, adjusted for sex, age, post-mortem interval (PMI), cause of death (DC), and pH. The sample includes both schizophrenia patients treated with clozapine (SZ-Clz) and control subjects (CTL), with dots colored blue for SZ-Clz patients and purple for CTL.

#### 267 3.4 NRN1 genetic variability effects

We found that incorporating two genetic variants, rs2208870 and rs12333117, along with LC1 scores or the "negative mean" values from the PFC sPLS-DA model, enhanced the correlation with *NRN1* gene expression in the corresponding brain region in the sample including SZ-Clz and CTL groups. Adding LC1 scores alongside the two genetic variants significantly enhanced the model's performance compared to using only the methylation variable (model's F=11.3, Adj-R<sup>2</sup>=0.673, p=0.001;  $\Delta$ -R<sup>2</sup>=0.137, p of the change=0.048). LC1 scores exhibited a robust association with NRN1 gene expression (standardized  $\beta$ =0.770, p<0.001), while the genetic variants also made significant contributions (standardized  $\beta$ =-0.404, p=0.029 for rs2208870;

275 standardized  $\beta$ =-0.364, p=0.045 for rs12333117). Similar improvements were observed when incorporating 276 the "negative mean" values alongside the two genetic variants, significantly enhancing the model's 277 performance compared to using only the methylation variable (model's F=12.52, Adj-R<sup>2</sup>=0.697, p=0.001;  $\Delta$ -R<sup>2</sup>=0.221, p of the change=0.015). The "negative mean" exhibited a strong association with NRN1 gene 278 expression (standardized  $\beta$ =0.790, p<0.001), while the genetic variants also made notable contributions 279 280 (standardized  $\beta$ =-0.490, p=0.010 for rs2208870; standardized  $\beta$ =-0.442, p=0.016 for rs12333117). 281 Conversely, we found that incorporating genotypic variability into the methylation metric did not enhance the 282 model's ability to explain NRN1 expression in the HIPP.

#### 283 4. Discussion

Given the crucial roles of *NRN1* in brain development and synaptic plasticity, and the significance of these mechanisms in the etiology of SZ, we have investigated the molecular variability of this gene in post-mortem brain samples from patients with SZ and CTL. Our study reveals that *NRN1* is significantly under-expressed in the PFC of patients treated with clozapine and that methylation levels correlate with *NRN1* expression in the same region. In addition, our study shows that incorporating genetic variability data of *NRN1* further shapes this correlation, highlighting the necessity of multi-level approaches to understand the role of candidate genes in SZ etiology.

First, our results showed that patients treated with clozapine exhibited reduced expression of NRN1 in the PFC 291 292 as compared to both CTL and Sz-ApFree patients. On the one hand, these differences should be considered 293 in terms of the their functional impact, as NRN1 expression is crucial as it enhances synaptic transmission by 294 increasing the surface expression of CaV1.2, CaV1.3, and CaV3.3 channels, mediated through the insulin 295 receptor and ERK signaling pathways (46-48). Then, our data provides new evidence suggesting that the 296 reduced NRN1 PFC expression observed in patients with SZ may be specifically associated with, or at least 297 more pronounced under, clozapine treatment, and that such differences could be related to synaptic 298 transmission variability. Despite the scarcity of comparable studies, to further interpretating our findings it is 299 interesting to mention that epigenetic mechanisms have been implicated in the effects of atypical antipsychotic 300 treatment, specifically demonstrating that chronic treatment induces the expression of proteins related to 301 histones deacetylation, such as HDAC2 (49). Particularly, clozapine treatment has been related to widespread 302 promoter demethylation (50). Also, it is remarkable a previous study exploring dorsolateral PFC transcriptome 303 of schizophrenia patients, that identified two molecularly distinct subgroups of patients, one similar to CTL and 304 the other markedly different, with NRN1 being among the down-regulated genes between the latter subgroup 305 and CTL (25). Then, we tried to replicate our results with a larger sample of clozapine-treated patients, but

public data was limited and had fewer treated patients than our study (GSE224683, GSE80655, GSE12649). On the other hand, the fact that our study did not reveal the same effect in HIPP, is aligned with previous research showing different anatomical methylation signatures in patients with SZ and CTL when comparing the PFC and the HIPP, possibly due to varying cellular compositions and their corresponding functional specializations (51). This interpretation within the framework of region-specific transcriptome alterations in SZ mirrors the loss-of-function mutations in the *GRIN2A* gene, encoding an NMDA receptor subunit, which significantly increase SZ risk by differentially affecting brain regions and circuits (52,53).

313 Second, we explored the methylation profile of NRN1 in the two brain regions, but recognizing the complexity 314 of interpreting methylation changes in SZ, in a complementary approach to the global perspective given by the PLS, we advanced to more detailed interpretations to integrate both broad methylation patterns and targeted 315 site-specific analyses. As regards the differences between SZ-Clz and CTL, defined by distinct CpG units in 316 317 each region, we observed that the component LC1, which best distinguished the two groups, included CpG 318 units with both increased and decreased methylation in patients, indicating that bidirectional changes are a 319 defining feature of the patient methylation profile across both brain regions. However, upon grouping CpG 320 units by the direction of methylation change, we found that the average of those CpG units under-methylated 321 in SZ-Clz was significantly different between groups in both regions, suggesting that lower methylation in SZ-322 Clz may play a more prominent role. Notably, a methylome-wide study identified a large region 323 (chr6:59992669-6006917) encompassing 29 adjacent CpG sites along the gene body of the NRN1 as 324 hypomethylated in PFC of SZ patients compared to CTL (26). This region included all CpG sites detected as 325 hypomethylated in our study except for CpG 1.3, hence our findings add to those from Pidsley et al., 2014 326 while also suggesting that the observed hypomethylation may be characteristic of clozapine-treated patients.

327 Third, when exploring the relationship between NRN1 methylation and expression patterns, we observed that 328 two methylation metrics derived from the PFC model, LC1 and the average of those CpG units under-329 methylated correlated with NRN1 expression in this region. Although the novelty of our study limits direct 330 comparison with other NRN1-specific results, our findings are consistent with previous research linking DNA 331 methylation to differential gene expression in post-mortem brain samples from individuals with SZ (54). 332 Additionally, it is important to note that some studies have linked clozapine treatment, but not haloperidol or 333 olanzapine, to changes in BDNF expression, an upstream regulator of NRN1, through the reduction of its 334 promoter methylation (55).

335 Next, to gain further insights into the potential methylation-expression correlates, we identified regulatory 336 elements overlapping with CpG units within PFC LC1 by using the UCSC Genome Browser

337 (http://genome.ucsc.edu) to access data from the Encyclopedia of DNA Elements (ENCODE) project (56) and 338 the Open Regulatory Annotation (ORegAnno) database (57). The presence of enhancer regions, DNase I 339 hypersensitive sites within these CpG units, and histone marks like H3K27me3, H3K4me1, and H3K36me3 340 highlights their potential in gene expression control and chromatin accessibility. Upon examining the 341 transcription factor binding sites (TFBS) influenced by these CpGs, we observed that most of the CpGs under-342 methylated in SZ-Clz potentially altered the binding of numerous transcription factors (TFs). Many of these TF have been previously associated with SZ. For instance, CpG1.3 methylation variability may impact the binding 343 344 of ELK1, differentially expressed in SZ lymphoblastoid cells (58), FEV, linked to affective disorders (59), and 345 SPDEF, which methylation moderates stress and substance abuse and its expression differs in the brain of 346 patients with autism spectrum disorders and CTL (60). Similarly, CpG2.5 and CpG2.6 could affect the binding 347 of EGR1, a stress response gene genetically associated with SZ (61).

Four, considering that many SZ-associated genetic variants have regulatory functions and that methylation is under local genetic control (62), we integrated genotypic variability in our analysis In the PFC, two variants (rs2208870 and rs12333117) along with LC1 scores or hypomethylated CpG units correlated with *NRN1* expression. HaploReg v4.2 data (63) showed that both variants alter TF binding affinity, with rs12333117 also affecting enhancer and promoter function in multiple tissues, including the brain.

353 Despite the insights gained into the effects of genetic variability and methylation patterns on NRN1 expression 354 in SZ, several limitations must be mentioned. Our relatively small sample size, although comparable to other studies, may not capture the full variability of the methylation landscape in SZ, limiting the generalizability of 355 356 our findings. Additionally, the expression and methylation relationship with antipsychotics is two-way: antipsychotics can modulate methylation and thereby gene expression, but the unique methylation profile of 357 358 an individual prior to treatment can also affect drug efficacy. Thus, without a group of never-treated patients, 359 we cannot truly separate the effects of the disorder from those of the medication, but finding such post-mortem 360 brain samples is challenging. Moreover, post-mortem samples also introduce variability due to tissue 361 heterogeneity and differences in the cause of death, though we tried to account for this by including this last 362 as a covariate. Finally, our cross-sectional study design limits our ability to assess changes in methylation over 363 time, which is crucial for understanding SZ progression and treatment response. Moreover, establishing 364 causality in such studies remains difficult. Therefore, further research with larger samples, longitudinal design, 365 and advanced multi-omics approaches are needed to fully understand the epigenetic mechanisms underlying 366 SZ.

In conclusion, we found that *NRN1* is significantly under-expressed in the PFC of patients with SZ treated with clozapine, with methylation levels correlating with its expression. Our study underscores distinct *NRN1* epigenetic patterns in the PFC and HIPP, highlighting the brain region specificity of SZ-related alterations. Additionally, incorporating genetic variability enhanced these correlations, emphasizing the importance of considering both genetic and epigenetic factors to fully understand the molecular mechanisms underlying SZ.

## 372 6. ACKNOWLEDGEMENTS

This work was supported by: i) Fundación Alicia Koplowitz, ii) Acadèmia de les Ciències Mèdiques i de la Salut de Catalunya i de Balears. This study also received funding provided by: i) the Instituto de Salud Carlos III through a Miguel Servet contract to MF–V (CP20/00072), co-funded by European Regional Development Fund (ERDF)/European Social Fund "Investing in your future"; (i) the Acadèmia de les Ciències Mèdiques i de la Salut de Catalunya i de Balears through a contract to CA-P; iii) the Comissionat per a Universitats i Recerca del DIUE of the Generalitat de Catalunya, Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR: 2021SGR1475); iv) the Basque Government (IT1512/22).

#### 380 7. ETHICAL STATEMENTS

The study adhered to legal and ethical standards, with all samples collected at the Basque Institute of Legal Medicine (Bilbao, Spain) in accordance with Spanish national research policies and ethical guidelines for postmortem brain studies in effect at the time of collection (Law 14/2007). Additional approval was obtained from the Research Ethics Committees of the Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU) in País Vasco, Spain (RD 1716/2011), and Germanes Hospitalaries in Cataluña, Spain (PR-2016-07).

## 386 8. CONFLICT OF INTERESTS

387 All the authors reported no biomedical financial interests or potential conflicts of interest.

### 388 9. AUTHORSHIP CONTRIBUTION STATEMENT

389 Carmen Almodóvar-Payá: Conceptualization, Data curation, Methodology, Investigation, Formal Analysis, 390 Visualization, Writing – original draft, Writing – review & editing. Marcos Moreno: Data Curation, Methodology, 391 Investigation, Formal Analysis, Writing - review & editing. Maria Guardiola-Ripoll: Data Curation, Investigation, Writing – review & editing. Mariona Latorre-Guardia: Methodology, Formal Analysis, Writing – 392 review & editing. Benito Morentin: Data curation, Resources, Writing - review & editing. Beatriz Garcia-393 394 Ruíz: Investigation, Writing – review & editing. Edith Pomarol-Clotet: Resources, Funding acquisition, Writing - review & editing. Luis F Callado: Data Curation, Resources, Funding acquisition, Writing - review & editing. 395 396 Carme Gallego: Conceptualization, Investigation, Methodology, Resources, Funding acquisition, Supervision,

- 397 Writing review & editing. Mar Fatjó-Vilas: Conceptualization, Methodology, Resources, Funding acquisition,
- 398 Supervision, Writing original draft, Writing review & editing.

#### 399 10. BIBLIOGRAPHY

- Hilker R, Helenius D, Fagerlund B, Skytthe A, Christensen K, Werge TM, et al. Heritability of Schizophrenia and Schizophrenia Spectrum Based on the Nationwide Danish Twin Register. Biological Psychiatry. 2018 Mar;83(6):492–8.
- Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a Complex Trait: Evidence From a Meta-analysis
   of Twin Studies. Arch Gen Psychiatry. 2003 Dec 1;60(12):1187.
- 405 3. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, et al. Common polygenic 406 variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009 Aug;460(7256):748–52.
- 407 4. Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic 408 loci implicates genes and synaptic biology in schizophrenia. Nature. 2022 Apr;604(7906):502–8.
- Takata A, Matsumoto N, Kato T. Genome-wide identification of splicing QTLs in the human brain and their
   enrichment among schizophrenia-associated loci. Nat Commun. 2017 Feb 27;8(1):14519.
- 411 6. Moore LD, Le T, Fan G. DNA Methylation and Its Basic Function. Neuropsychopharmacol. 2013 412 Jan;38(1):23–38.
- 413 7. Halder R, Hennion M, Vidal RO, Shomroni O, Rahman RU, Rajput A, et al. DNA methylation changes in plasticity genes accompany the formation and maintenance of memory. Nat Neurosci. 2016
  415 Jan;19(1):102–10.
- 416 8. Sun M an, Sun Z, Wu X, Rajaram V, Keimig D, Lim J, et al. Mammalian Brain Development is 417 Accompanied by a Dramatic Increase in Bipolar DNA Methylation. Sci Rep. 2016 Sep 2;6(1):32298.
- Richetto J, Meyer U. Epigenetic Modifications in Schizophrenia and Related Disorders: Molecular Scars of Environmental Exposures and Source of Phenotypic Variability. Biological Psychiatry. 2021 Feb 1;89(3):215–26.
- Merikangas AK, Shelly M, Knighton A, Kotler N, Tanenbaum N, Almasy L. What genes are differentially
  expressed in individuals with schizophrenia? A systematic review. Mol Psychiatry. 2022 Mar;27(3):1373–
  83.
- 11. Collado-Torres L, Burke EE, Peterson A, Shin J, Straub RE, Rajpurohit A, et al. Regional Heterogeneity
   in Gene Expression, Regulation, and Coherence in the Frontal Cortex and Hippocampus across
   Development and Schizophrenia. Neuron. 2019 Jul 17;103(2):203-216.e8.
- Huang HS, Akbarian S. GAD1 mRNA Expression and DNA Methylation in Prefrontal Cortex of Subjects
   with Schizophrenia. PLOS ONE. 2007 Aug 29;2(8):e809.
- 429 13. Iwamoto K, Bundo M, Yamada K, Takao H, Iwayama-Shigeno Y, Yoshikawa T, et al. DNA Methylation
  430 Status of SOX10 Correlates with Its Downregulation and Oligodendrocyte Dysfunction in Schizophrenia.
  431 J Neurosci. 2005 Jun 1;25(22):5376–81.
- 432 14. Kordi-Tamandani DM, Sahranavard R, Torkamanzehi A. Analysis of association between dopamine
   433 receptor genes' methylation and their expression profile with the risk of schizophrenia. Psychiatric
   434 Genetics. 2013 Oct;23(5):183.
- 435 15. Kundakovic M, Chen Y, Costa E, Grayson DR. DNA Methyltransferase Inhibitors Coordinately Induce
  436 Expression of the Human Reelin and Glutamic Acid Decarboxylase 67 Genes. Mol Pharmacol. 2007 Mar
  437 1;71(3):644–53.
- 438 16. Putz U, Harwell C, Nedivi E. Soluble CPG15 expressed during early development rescues cortical
   439 progenitors from apoptosis. Nat Neurosci. 2005 Mar;8(3):322–31.

medRxiv preprint doi: https://doi.org/10.1101/2024.10.29.24315982; this version posted November 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

#### perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 440 17. Javaherian A, Cline HT. Coordinated motor neuron axon growth and neuromuscular synaptogenesis are
   441 promoted by CPG15 in vivo. Neuron. 2005 Feb 17;45(4):505–12.
- Flavell SW, Greenberg ME. Signaling mechanisms linking neuronal activity to gene expression and plasticity of the nervous system. Annu Rev Neurosci. 2008;31:563–90.
- 444 19. Loebrich S, Nedivi E. The function of activity-regulated genes in the nervous system. Physiol Rev. 2009
   445 Oct;89(4):1079–103.
- 446 20. Hallmayer JF, Kalaydjieva L, Badcock J, Dragović M, Howell S, Michie PT, et al. Genetic Evidence for a
  447 Distinct Subtype of Schizophrenia Characterized by Pervasive Cognitive Deficit. The American Journal of
  448 Human Genetics. 2005 Sep 1;77(3):468–76.
- Almodóvar-Payá C, Guardiola-Ripoll M, Giralt-López M, Gallego C, Salgado-Pineda P, Miret S, et al.
   NRN1 Gene as a Potential Marker of Early-Onset Schizophrenia: Evidence from Genetic and
   Neuroimaging Approaches. International Journal of Molecular Sciences. 2022 Jan;23(13):7456.
- 452 22. Almodóvar-Payá C, Guardiola-Ripoll M, Giralt-López M, Oscoz-Irurozqui M, Canales-Rodríguez EJ,
   453 Madre M, et al. NRN1 epistasis with BDNF and CACNA1C: mediation effects on symptom severity through
   454 neuroanatomical changes in schizophrenia. Brain Struct Funct. 2024 Jun 1;229(5):1299–315.
- 455 23. Fatjó-Vilas M, Prats C, Pomarol-Clotet E, Lázaro L, Moreno C, González-Ortega I, et al. Involvement of
  456 NRN1 gene in schizophrenia-spectrum and bipolar disorders and its impact on age at onset and cognitive
  457 functioning. The World Journal of Biological Psychiatry. 2016 Feb 17;17(2):129–39.
- 458 24. Chandler D, Dragović M, Cooper M, Badcock JC, Mullin BH, Faulkner D, et al. Impact of Neuritin 1 (NRN1)
  459 polymorphisms on fluid intelligence in schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2010;153B(2):428–37.
- 461 25. Bowen EFW, Burgess JL, Granger R, Kleinman JE, Rhodes CH. DLPFC transcriptome defines two
   462 molecular subtypes of schizophrenia. Transl Psychiatry. 2019 May 9;9(1):1–10.
- Pidsley R, Viana J, Hannon E, Spiers H, Troakes C, Al-Saraj S, et al. Methylomic profiling of human brain
   tissue supports a neurodevelopmental origin for schizophrenia. Genome Biol. 2014;15(10):483.
- 27. Reshetnikov VV, Kisaretova PE, Ershov NI, Shulyupova AS, Oshchepkov DY, Klimova NV, et al. Genes
  associated with cognitive performance in the Morris water maze: an RNA-seq study. Sci Rep. 2020 Dec
  16;10(1):22078.
- 468 28. Wan K, Mao F, Li Q, Wang L, Wei Z, Wang P, et al. Neuritin-overexpressing transgenic mice demonstrate
  469 enhanced neuroregeneration capacity and improved spatial learning and memory recovery after ischemia470 reperfusion injury. Aging (Albany NY). 2020 Dec 15;13(2):2681–99.
- 471 29. Liu Y ping, Wu X, Xia X, Yao J, Wang B jie. The genome-wide supported CACNA1C gene polymorphisms
  472 and the risk of schizophrenia: an updated meta-analysis. BMC Medical Genetics. 2020 Aug 8;21(1):159.
- Alme MN, Wibrand K, Dagestad G, Bramham CR. Chronic Fluoxetine Treatment Induces Brain Region Specific Upregulation of Genes Associated with BDNF-Induced Long-Term Potentiation. Neural Plast.
   2007;2007:26496.
- 476 31. Park HG, Yu HS, Park S, Ahn YM, Kim YS, Kim SH. Repeated treatment with electroconvulsive seizures
  477 induces HDAC2 expression and down-regulation of NMDA receptor-related genes through histone
  478 deacetylation in the rat frontal cortex. International Journal of Neuropsychopharmacology. 2014 Sep
  479 1;17(9):1487–500.
- 480 32. Lally J, Ajnakina O, Forti MD, Trotta A, Demjaha A, Kolliakou A, et al. Two distinct patterns of treatment 481 resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses.
   482 Psychological Medicine. 2016 Nov;46(15):3231–40.
- 33. Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, et al. Efficacy, Acceptability, and
   Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. JAMA
   Psychiatry. 2016 Mar 1;73(3):199–210.

medRxiv preprint doi: https://doi.org/10.1101/2024.10.29.24315982; this version posted November 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

#### perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 486 34. de Bartolomeis A, Vellucci L, Barone A, Manchia M, De Luca V, Iasevoli F, et al. Clozapine's multiple
  487 cellular mechanisms: What do we know after more than fifty years? A systematic review and critical
  488 assessment of translational mechanisms relevant for innovative strategies in treatment-resistant
  489 schizophrenia. Pharmacology & Therapeutics. 2022 Aug 1;236:108236.
- 490 35. Guidotti A, Dong E, Grayson DR. Epigenetic Basis of Clozapine Action. 2017;
- 491 36. Lee BJ, Marchionni L, Andrews CE, Norris AL, Nucifora LG, Wu YC, et al. Analysis of differential gene
  492 expression mediated by clozapine in human postmortem brains. Schizophrenia Research. 2017
  493 Jul;185:58–66.
- 494 37. Prats C, Arias B, Ortet G, Ibáñez MI, Moya J, Pomarol-Clotet E, et al. Role of neurotrophins in depressive
   495 symptoms and executive function: Association analysis of NRN1 gene and its interaction with BDNF gene
   496 in a non-clinical sample. Journal of Affective Disorders. 2017 Mar 15;211:92–8.
- 497 38. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: A Tool Set for Whole498 Genome Association and Population-Based Linkage Analyses. Am J Hum Genet. 2007 Sep;81(3):559–
  499 75.
- 39. Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR
   and the 2-ΔΔCT Method. Methods. 2001 Dec 1;25(4):402–8.
- 40. Redlich R, Schneider I, Kerkenberg N, Opel N, Bauhaus J, Enneking V, et al. The role of BDNF methylation
  and Val66Met in amygdala reactivity during emotion processing. Human Brain Mapping. 2020;41(3):594–
  604.
- 41. Thompson M, Hill BL, Rakocz N, Chiang JN, Geschwind D, Sankararaman S, et al. Methylation risk scores
   are associated with a collection of phenotypes within electronic health record systems. npj Genom Med.
   2022 Aug 25;7(1):1–11.
- 42. Rohart F, Gautier B, Singh A, Cao KAL. mixOmics: An R package for 'omics feature selection and multiple
   data integration. PLOS Computational Biology. 2017 Nov 3;13(11):e1005752.
- 43. Morgan SE, Seidlitz J, Whitaker KJ, Romero-Garcia R, Clifton NE, Scarpazza C, et al. Cortical patterning
  of abnormal morphometric similarity in psychosis is associated with brain expression of schizophreniarelated genes. Proceedings of the National Academy of Sciences. 2019 May 7;116(19):9604–9.
- 44. Fernandez-Egea E, Vértes PE, Flint SM, Turner L, Mustafa S, Hatton A, et al. Peripheral Immune Cell
  Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant
  Schizophrenia. PLOS ONE. 2016 May 31;11(5):e0155631.
- 45. Rizig MA, McQuillin A, Ng A, Robinson M, Harrison A, Zvelebil M, et al. A gene expression and systems
  pathway analysis of the effects of clozapine compared to haloperidol in the mouse brain implicates
  susceptibility genes for schizophrenia. J Psychopharmacol. 2012 Sep 1;26(9):1218–30.
- 46. Lu JM, Liu DD, Li ZY, Ling C, Mei YA. Neuritin Enhances Synaptic Transmission in Medial Prefrontal
  Cortex in Mice by Increasing CaV3.3 Surface Expression. Cerebral Cortex. 2017 Jul 1;27(7):3842–55.
- 47. Yao JJ, Gao XF, Chow CW, Zhan XQ, Hu CL, Mei YA. Neuritin Activates Insulin Receptor Pathway to Up regulate Kv4.2-mediated Transient Outward K+ Current in Rat Cerebellar Granule Neurons \*. Journal of
   Biological Chemistry. 2012 Nov 30;287(49):41534–45.
- 48. Zhao QR, Lu JM, Li ZY, Mei YA. Neuritin promotes neurite and spine growth in rat cerebellar granule cells via L-type calcium channel-mediated calcium influx. Journal of Neurochemistry. 2018;147(1):40–57.
- 49. Ibi D, de la Fuente Revenga M, Kezunovic N, Muguruza C, Saunders JM, Gaitonde SA, et al.
   Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects. Nat
   Neurosci. 2017 Sep;20(9):1247–59.
- 529 50. Dong E, Nelson M, Grayson DR, Costa E, Guidotti A. Clozapine and sulpiride but not haloperidol or 530 olanzapine activate brain DNA demethylation. Proceedings of the National Academy of Sciences of the 531 United States of America. 2008 Aug 29;105(36):13614.

medRxiv preprint doi: https://doi.org/10.1101/2024.10.29.24315982; this version posted November 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

#### perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 51. Alelú-Paz R, Carmona FJ, Sanchez-Mut JV, Cariaga-Martínez A, González-Corpas A, Ashour N, et al.
  Epigenetics in Schizophrenia: A Pilot Study of Global DNA Methylation in Different Brain Regions
  Associated with Higher Cognitive Functions. Front Psychol [Internet]. 2016 Sep 30 [cited 2024 Jan 8];7.
  Available from: http://journal.frontiersin.org/Article/10.3389/fpsyg.2016.01496/abstract
- 536 52. Farsi Z, Nicolella A, Simmons SK, Aryal S, Shepard N, Brenner K, et al. Brain-region-specific changes in neurons and glia and dysregulation of dopamine signaling in Grin2a mutant mice. Neuron. 2023 Nov 1;111(21):3378-3396.e9.
- 539 53. Huckins LM, Dobbyn A, Ruderfer DM, Hoffman G, Wang W, Pardiñas AF, et al. Gene expression
  imputation across multiple brain regions provides insights into schizophrenia risk. Nat Genet. 2019
  541 Apr;51(4):659–74.
- 54. Chen C, Zhang C, Cheng L, Reilly JL, Bishop JR, Sweeney JA, et al. Correlation between DNA methylation
  and gene expression in the brains of patients with bipolar disorder and schizophrenia. Bipolar Disorders.
  2014;16(8):790–9.
- 545 55. Dong E, Tueting P, Matrisciano F, Grayson DR, Guidotti A. Behavioral and molecular neuroepigenetic 546 alterations in prenatally stressed mice: relevance for the study of chromatin remodeling properties of 547 antipsychotic drugs. Transl Psychiatry. 2016 Jan;6(1):e711–e711.
- 548 56. Dunham I, Kundaje A, Aldred SF, Collins PJ, Davis CA, Doyle F, et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012 Sep;489(7414):57–74.
- 57. Griffith OL, Montgomery SB, Bernier B, Chu B, Kasaian K, Aerts S, et al. ORegAnno: an open-access
  community-driven resource for regulatory annotation. Nucleic Acids Res. 2008 Jan;36(Database
  issue):D107–13.
- 58. Kyosseva SV, Elbein AD, Hutton TL, Griffin WST, Mrak RE, Sturner WQ, et al. Increased Levels of Transcription Factors Elk-1, Cyclic Adenosine Monophosphate Response Element-Binding Protein, and Activating Transcription Factor 2 in the Cerebellar Vermis of Schizophrenic Patients. Archives of General Psychiatry. 2000 Jul 1;57(7):685–91.
- 557 59. Kriegebaum CB, Gutknecht L, Bartke L, Reif A, Buttenschon HN, Mors O, et al. The expression of the
  transcription factor FEV in adult human brain and its association with affective disorders. J Neural Transm.
  2010 Jul 1;117(7):831–6.
- 560 60. Tay N, Macare C, Liu Y, Ruggeri B, Jia T, Chu C, et al. Allele-Specific Methylation of SPDEF: A Novel
   561 Moderator of Psychosocial Stress and Substance Abuse. AJP. 2019 Feb;176(2):146–55.
- 562 61. Duclot F, Kabbaj M. The Role of Early Growth Response 1 (EGR1) in Brain Plasticity and Neuropsychiatric
   563 Disorders. Front Behav Neurosci [Internet]. 2017 Mar 6 [cited 2024 Jul 26];11. Available from:
   564 https://www.frontiersin.org/journals/behavioral-neuroscience/articles/10.3389/fnbeh.2017.00035/full
- 565 62. Gaunt TR, Shihab HA, Hemani G, Min JL, Woodward G, Lyttleton O, et al. Systematic identification of 566 genetic influences on methylation across the human life course. Genome Biol. 2016 Mar 31;17(1):61.
- 63. Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Res. 2016 Jan 4;44(Database issue):D877–81.

570